Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Canagliflozin for Post-Bariatric T2D
NCT02912455Phase 4Terminated
- Sponsor
- Cleveland Clinic
- Start
- Jan 2017
- Primary completion
- Jul 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Canagliflozin with Placebo (2 arms). Primary endpoint: Change in Hemoglobin A1c at 6 months. Started Jan 2017; status: terminated.
02
Drugs
canagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02912455.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02912455.